Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 184 matching trials from the live ClinicalTrials.gov search.
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
dutasteride
Drug
Lead sponsor
Urology of Virginia
Other
Eligibility
50 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Norfolk, Virginia • Virginia Beach, Virginia
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions
MCS-2 15 mg/day, MCS-2 30 mg/day, Placebo
Drug
Lead sponsor
Health Ever Bio-Tech Co., Ltd.
Industry
Eligibility
40 Years and older · Male only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostatic Hyperplasia
Interventions
GI198745
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Benign Prostatic Hypertrophy
Interventions
Richard Wolf 24F Laser scope, Karl Storz 28F Laser Scope
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Benign Prostatic Hyperplasia
Interventions
S-equol, Placebo
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
50 Years and older · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Huntsville, Alabama • Aventura, Florida • Clearwater, Florida + 2 more
Conditions
Voiding Disorders
Interventions
Simultaneous functional MRI and urodynamic studies, Questionnaires, Post Void Residual (PVR), Uroflow and Bladder Diary, Urinalysis
Diagnostic Test · Behavioral · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 90 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Bladder Outlet Obstruction
Interventions
Toviaz (Fesoterodine)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 99 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound
Other
Lead sponsor
Medi-Tate Ltd.
Industry
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Pompano Beach, Florida • Manhattan, New York • New York, New York
Conditions
Bladder Cancer
Interventions
biopsy, therapeutic conventional surgery
Procedure
Lead sponsor
Roei Medical Technologies Ltd.
Industry
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Hematuria, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
PuraStat
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Carcinoma, Benign Prostatic Hyperplasia
Interventions
Merit Medical Embospheres, Radiation Therapy
Device · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
50 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Benign Prostatic Hypertrophy
Interventions
Cetrorelix Pamoate
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
50 Years and older · Male only
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
56
States / cities
Homewood, Alabama • Huntsville, Alabama • Laguna Hills, California + 49 more
Conditions
Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Interventions
ozarelix, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
50 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Benign Prostatic Hyperplasia
Interventions
Urolift
Device
Lead sponsor
Northwell Health
Other
Eligibility
50 Years to 99 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Syosset, New York
Conditions
Benign Prostatic Hyperplasia
Interventions
Saw Palmetto
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Conditions
Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Male Urogenital Diseases, Genital Diseases, Male, Prostatic Disease, Prostatic Hyperplasia
Interventions
SoracteLite(TM) TPLA for BPH
Device
Lead sponsor
Urological Research Network, LLC
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Hialeah, Florida
Conditions
Benign Prostatic Hyperplasia
Interventions
WC3055, Placebo
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years and older · Male only
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
95
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 80 more
Conditions
BPH (Benign Prostatic Hyperplasia)
Interventions
Zenflow Spring System
Device
Lead sponsor
Zenflow, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Phoenix, Arizona • La Mesa, California • Tampa, Florida + 5 more
Conditions
Benign Prostatic Hyperplasia With Outflow Obstruction, Urinary Retention, Lower Urinary Tract Symptoms
Interventions
Preoperative pelvic floor physical therapy
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Austin, Texas
Completed Phase 3 Interventional Accepts healthy volunteers

Medical Therapy of Prostatic Symptoms

NCT00021814
Conditions
Prostatic Hyperplasia, Prostatic Hypertrophy, Benign
Interventions
Doxazosin, Finasteride, Doxazosin placebo, Finasteride placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
3,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2001
U.S. locations
17
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 13 more
Conditions
BPH, Erectile Dysfunction
Interventions
Alfuzosin 10 mg
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Terminated Phase 2 Interventional Results available

A Study in Men With Benign Prostatic Hyperplasia

NCT01097707
Conditions
Benign Prostatic Hyperplasia
Interventions
LY500307, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendora, California + 37 more